Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Eli Lilly’s obesity and diabetes treatments fuel growth and spark bidding war

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales

Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year ...

Investor Outlook: Eli Lilly delivers another strong quarter as demand for GLP-1 drugs accelerates

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

Eli Lilly Reports Earnings Thursday as Investors Await Trump Drug Pricing Deal

The drugmaker Eli Lilly reports its third-quarter results early Thursday, as questions loom about what kind of deal it will reach with the Trump administration over the price of its weight-loss drug.

How Omvoh’s FDA Approval at Eli Lilly (LLY) Has Changed Its Investment Story

On October 27, 2025, Eli Lilly announced that the U.S. FDA approved a new, once-monthly single-injection maintenance regimen ...